Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores
- PMID: 29871660
- PMCID: PMC5989334
- DOI: 10.1186/s13054-018-2084-z
Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores
Conflict of interest statement
Ethics approval and consent to participate
The study protocol of the Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (SISPCT) was approved by the ethics board of Jena University Hospital (Internal File No. 2242–03/08). Written informed consent was obtained from all patients or their legal representatives.
Consent for publication
No individual participant data are reported that would require consent to publish from the participant (or legal parent or guardian for children).
Competing interests
FB reported receiving lecture honoraria from biosyn, Gilead, and CSL Behring and public funding for the SISPCT trial to his department by the German Federal Ministry of Education and Research as well as unrestricted research grants for the SISPCT trial by biosyn and Thermo Fisher Scientific. DCW is an employee of B·R·A·H·M·S GmbH. All other authors declared that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures

References
-
- Bernal-Morell E, García-Villalba E, Vera MDC, et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Inf Secur. 2018;76:249–257. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical